Climb Bio

Climb Bio Forward P/E

The Forward P/E Ratio of Climb Bio (CLYM) as of Nov 19, 2026 is -6.46. In the previous year, Forward P/E Ratio was -5.23 — a change of 23.47% (lower).

Forward P/E

-6.46

YoY

23.47%

Last updated:

Forward P/E Ratio of Climb Bio is 2025 -6.46 . Forward P/E Ratio of Climb Bio was 2024 -5.23 . It decreases by 23.47% lower compared to the previous year.

The Climb Bio Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-59.05 USD
Jan 1, 2020
-18.71 USD
Jan 1, 2021
-8.14 USD
Jan 1, 2022
-8.54 USD
Jan 1, 2023
-11.01 USD
Jan 1, 2024
-5.23 USD
Jan 1, 2025
-6.46 USD
The Climb Bio Forward P/E history
YEARForward P/EYoY
-6.46+23.47%
-5.23-52.48%
-11.01+28.83%
-8.54+4.94%
-8.14-56.47%
-18.71-68.32%
-59.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Climb Bio Stock analysis

What does Climb Bio do? Eliem Therapeutics, Inc. develops novel therapies for neuronal excitability disorders, targeting unmet needs in psychiatry, epilepsy, chronic pain, and nervous system disorders. Its lead product ETX-123, a Kv7.2/3 potassium channel opener, is designed to improve safety and tolerability over earlier molecules while leveraging clinically validated mechanisms. The company focuses on validated mechanisms of action with therapeutic potential for patients with these conditions. ETX-123 is a generate new chemical entities candidate that harnesses the efficacy of Kv7.2/3 channel mechanism, with encouraging clinical data in depression, epilepsy, and pain. The company's pipeline includes clinically differentiated product candidates targeting validated therapeutic targets to deliver improved therapeutics. Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Wilmington, Delaware, with 30 full-time employees. The company's revenue model is not disclosed in the business description, as it is a clinical-stage biotechnology firm focused on research and development rather than commercial product sales. Its primary focus is on advancing its pipeline through clinical trials to achieve regulatory approvals and potential future partnerships or sales. Climb Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Climb Bio stock

Forward P/E Ratio of Climb Bio is -6.46 in 2025.

Forward P/E Ratio of Climb Bio changed from -5.23 to -6.46, representing a 23.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Climb Bio since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Climb Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Climb Bio

All Key Metrics — Climb Bio